Release date: March 7, 2024



and the second s							
	2018	2019	2020	2021	2022	Period Increase (+) / decrease (-)	% Period Increase (+) / decrease (-)
pooling of high cost drug claim experience for CDIPC member insurance companies							
3 plan high cost drug claim experience (certificates exceeding \$10K in drug claims	s paid annual	ly)					
Quebec ¹						[2018 -	2022]
% of total drug claim dollars paid	38.5%	42.4%	44.0%	47.4%	44.9%	6.4%	16.7%
% plan members with high cost drug claims	1.9%	2.2%	2.5%	2.6%	2.5%	0.6%	32.0%
Pharmacare provinces % of total drug claim dollars paid	11.5%	12.5%	13.8%	14.2%	15.4%	3.8%	33.3%
% plan members with high cost drug claims	0.3%	0.3%	0.4%	0.4%	0.5%	0.2%	49.7%
Non-pharmacare provinces & excluding Quebec							
% of total drug claim dollars paid	31.1%	31.9%	34.2%	34.7%	34.7%	3.5%	11.4%
% plan members with high cost drug claims	1.1%	1.2%	1.4%	1.5%	1.5%	0.4%	36.8%
# of plan members from all of Canada with high-cost drugs when drug paid is \geq \$10K							
\$10-32.5K	18,688	20,696	22,960	24,739	26,874	8,186	43.8%
\$32.5-65K	3,293 514	3,449 555	3,779 613	3,904 613	4,046 600	753 86	22.9% 16.7%
\$65-100K \$100-400K	297	333	399	437	534	237	79.8%
\$400-620.7K	13	21	29	23	29	16	123.1%
\$620.7-750K	4	5	6	7	8	4	100.0%
\$750K-1M	3	3 2	4 6	8 6	9	6 2	200.0% 100.0%
STM+		25,064	27,796	29,737	32,104	9,290	40.7%
\$1M+ Total	22,814						
Total Year over year growth	22,814	9.9%	10.9%	7.0%	8.0%		
Total	12,076		10.9% 14,464	7.0% 13,891	8.0% 15,088	3,012	24.9%
Total Year over year growth		9.9%				3,012	24.9%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed		9.9%				3,012	
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member ¹		9.9%					2022]
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts	12,076	9.9%	14,464	13,891	15,088	[2018 - 60	2022] 12.3%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018	12,076	9.9% 13,253 510	14,464	13,891	15,088	[2018 - 60	2022 J 12.3%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience	12,076 487	9.9% 13,253 510	14,464 529	13,891 527 38	15,088 547 29	[2018 - 60 [2018 - -36	2022] 12.3% 2022] -55.4%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018	12,076	9.9% 13,253 510	14,464	13,891	15,088	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members	12,076 487 65 451	9.9% 13,253 510 46 1,233	14,464 529 37 2,143	13,891 527 38 2,879	15,088 547 29 3,597	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854	14,464 529 37 2,143 \$44.6 \$20,809	13,891 527 38 2,879 \$58.6 \$20,359	15,088 547 29 3,597 \$72.5 \$20,154	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854	14,464 529 37 2,143 \$44.6 \$20,809	13,891 527 38 2,879 \$58.6 \$20,359	15,088 547 29 3,597 \$72.5 \$20,154	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -2022] -48.1%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854	14,464 529 37 2,143 \$44.6 \$20,809	13,891 527 38 2,879 \$58.6 \$20,359	15,088 547 29 3,597 \$72.5 \$20,154	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -48.1% 411.3%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186	14,464 529 37 2,143 \$44.6 \$20,809 28 535	13,891 527 38 2,879 \$58.6 \$20,359 25 739	15,088 547 29 3,597 \$72.5 \$20,154 27 951	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -2022] -48.1% 411.3% 208.7%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088	[2018 - 60 [201836 3,146 61 -\$5,413 [2019 -25 765 19 -\$19,740 [2020 -	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -48.1% 411.3% 208.7% -39.6%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$552,644	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36	[2018 - 60 [201836 3,146 61 -\$5,413 [2019 -25 765 19 -\$19,740 [2020-	2022] 12.39 2022] -55.49 697.69 528.79 -21.29 -48.19 411.39 208.79 -39.69 -2022] 34.59
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088	[2018 - 60 [201836 3,146 61 -\$5,413 [2019 -25 765 19 -\$19,740 [2020 -	2022]
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 517	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887	[2018 - 60 [201836 3,146 61 -\$5,413 [2019 -25 765 19 -\$19,740 [2020 - 19 678 17 -\$5,538	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -2022] -48.1% 411.3% 208.7% -39.6% -2022] 34.5% 324.4% -17.2%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M)	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 517 \$14.8	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -2022] -48.1% 411.3% 208.7% -39.6% -2022] 34.5% 324.4% -17.2%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Claimed by # plan members Claimed by # plan members	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 517 \$14.8 \$28,627 57 176	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757	[2018 - 60	2022]
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M)	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 \$17 \$14.8 \$28,627 57 176 \$6.8	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757 \$58.0	[2018 - 60	2022] 12.3% 2022] -55.4% 697.6% 528.7% -21.2% -2022] -48.1% 411.3% 208.7% -39.6% -2022] 34.5% 324.4% 251.4% -17.2% -2022] -47.4% 330.1% 746.2%
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 517 \$14.8 \$28,627 57 176	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757	[2018 - 60	2022]
Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims ph cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 \$17 \$14.8 \$28,627 57 176 \$6.8	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757 \$58.0 \$76,559	[2018 - 60	2022]
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient Al) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 \$17 \$14.8 \$28,627 57 176 \$6.8	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757 \$58.0	[2018 - 60	2022]
Total Year over year growth # plan sponsors w/one or more plan members having high-cost drug claims gh cost / specialty drugs in excess of \$10K per plan member # high cost drugs claimed (based on Active Ingredient AI) code, so multiple dosages or different marketing's of same of same drug counted only once) High cost drug pipeline impacts For drugs that were first paid in 2018 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2019 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2020 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2021 # of drugs new to EP3 claim experience Claimed by # plan members Who had drugs covered totalling (claims paid \$M) With an average amount paid per certificate of For drugs that were first paid in 2022 # of drugs new to EP3 claim experience	12,076 487 65 451 \$11.5	9.9% 13,253 510 46 1,233 \$29.4 \$23,854 52 186 \$9.3	14,464 529 37 2,143 \$44.6 \$20,809 28 535 \$28.2 \$52,644 55 209 \$6.7	13,891 527 38 2,879 \$58.6 \$20,359 25 739 \$35.2 \$47,675 38 \$17 \$14.8 \$28,627 57 176 \$6.8	15,088 547 29 3,597 \$72.5 \$20,154 27 951 \$28.6 \$30,088 36 887 \$23.6 \$26,644 30 757 \$58.0 \$76,559	[2018 - 60	2022]

	2018	2019	2020	2021	2022	Period Increase (+) / decrease (-)	% Period Increase (+) / decrease (-)
Industry pool portion shared between CDIPC member companies (a subset of EP3 pooling)							
Industry pool thresholds and pooling maximum							
Initial threshold Ongoing threshold and EP3 pooling endpoint Pooling maximum Industry pool experience ²	\$65,000 \$32,500 \$500,000	\$65,000 \$32,500 \$500,000	\$65,000 \$32,500 \$500,000	\$65,001 \$32,500 \$500,001	\$65,000 \$32,500 \$500,000		0.0% 0.0% 0.0%
mustry poor experience						[2018 -	- 2022]
# plan members w/paid claims greater than or equal to "Ongoing Threshold" (OT)	4,041	4,305	4,749	4,983	5,230		24.9%
Representing paid claims of \$ (M) # plan members qualified for industry pooling	\$238.1 470	\$259.2 513	\$300.9 637	\$312.0 749	\$349.2 763	\$111.1 293	46.7% 62.3%
% plan members that qualify to pool when paid claims ≥ OT # plan members qualified for 1st year of industry pooling	11.6% 156	11.9% 172	13.4% 256	15.0% 292	14.6% 244	88	56.4%
\$ pooled (M) # plan members qualified for 2 or more years of industry pooling \$ pooled (M)	\$8.6 314 \$12.4	\$8.1 341 \$14.0	\$12.5 381 \$16.6	\$13.5 457 \$21.1	\$11.4 519 \$24.1	\$2.8 205 \$11.7	32.6% 65.3% 94.4%

^{1 -} Estimated